| Year |
Citation |
Score |
| 2021 |
Goldstein LJ, Mansutti M, Levy C, Chang JC, Henry S, Fernandez-Perez I, Prausovà J, Staroslawska E, Viale G, Butler B, McCanna S, Ruffini PA, Wicha MS, Schott AF. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Research and Treatment. PMID 34476645 DOI: 10.1007/s10549-021-06367-5 |
0.343 |
|
| 2021 |
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 484-493. PMID 34030128 DOI: 10.6004/jnccn.2021.0023 |
0.366 |
|
| 2020 |
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 452-478. PMID 32259783 DOI: 10.6004/jnccn.2020.0016 |
0.351 |
|
| 2020 |
Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, Rosato RR, Chang JC. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Research : Bcr. 22: 4. PMID 31924241 DOI: 10.1186/s13058-019-1243-8 |
0.321 |
|
| 2020 |
Lewis B, Meeker CR, Handorf E, Filchner K, Seedor R, Winn JS, Goldstein LJ, Dotan E. HSR20-093: Psychosocial Support in Older Patients With Metastatic Breast Cancer (MBC) Treated at Community Centers Journal of the National Comprehensive Cancer Network. 18. DOI: 10.6004/Jnccn.2019.7483 |
0.306 |
|
| 2020 |
Khan SA, Zhao F, Solin LJ, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.18_Suppl.Lba2 |
0.3 |
|
| 2019 |
Varshavsky-Yanovsky AN, Goldstein LJ. Role of Capecitabine in Early Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 38: 179-182. PMID 31804861 DOI: 10.1200/JCO.19.02946 |
0.332 |
|
| 2019 |
Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, et al. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 118-126. PMID 30787125 DOI: 10.6004/jnccn.2019.0009 |
0.331 |
|
| 2019 |
Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical Breast Cancer. 19: 97-104.e4. PMID 30655172 DOI: 10.1016/j.clbc.2018.12.011 |
0.329 |
|
| 2018 |
Bleicher RJ, Chang C, Wang CE, Goldstein LJ, Kaufmann CS, Moran MS, Pollitt KA, Suss NR, Winchester DP, Tafra L, Yao K. Treatment delays from transfers of care and their impact on breast cancer quality measures. Breast Cancer Research and Treatment. PMID 30443881 DOI: 10.1007/s10549-018-5046-x |
0.304 |
|
| 2018 |
Martin JM, Goldstein LJ. Profile of abemaciclib and its potential in the treatment of breast cancer. Oncotargets and Therapy. 11: 5253-5259. PMID 30214230 DOI: 10.2147/OTT.S149245 |
0.32 |
|
| 2018 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 310-320. PMID 29523670 DOI: 10.6004/jnccn.2018.0012 |
0.319 |
|
| 2018 |
Verma N, Harding D, Mohammadi A, Goldstein LJ, Gilmore HL, Feldman MD, Tomaszewski J, Basavanhally A, Lloyd M, Fu P, Ganesan S, Davidson NE, Madabhushi A, Monaco J. Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197. Journal of Clinical Oncology. 36: 540-540. DOI: 10.1200/Jco.2018.36.15_Suppl.540 |
0.315 |
|
| 2017 |
Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Research and Treatment. PMID 28623430 DOI: 10.1007/S10549-017-4310-9 |
0.331 |
|
| 2017 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 433-451. PMID 28404755 DOI: 10.6004/JNCCN.2017.0044 |
0.305 |
|
| 2017 |
Wen K, Smith R, Padmanabhan A, Goldstein L. Patient experience of taking adjuvant endocrine therapy for breast cancer: a tough pill to swallow Patient Experience Journal. 4: 104-114. DOI: 10.35680/2372-0247.1173 |
0.329 |
|
| 2016 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 324-54. PMID 26957618 DOI: 10.6004/JNCCN.2016.0037 |
0.335 |
|
| 2016 |
Churilla T, Egleston B, Murphy C, Sigurdson E, Hayes S, Goldstein L, Bleicher R. Abstract P1-07-25: Patterns of multidisciplinary care in the management of nonmetastatic invasive breast cancer in the United States Medicare patient Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-07-25 |
0.317 |
|
| 2016 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Kelly Marcom P, et al. Invasive breast cancer version 1.2016 Jnccn Journal of the National Comprehensive Cancer Network. 14: 324-354. |
0.329 |
|
| 2015 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, et al. Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1475-1485. PMID 26656517 DOI: 10.6004/JNCCN.2015.0176 |
0.348 |
|
| 2015 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, et al. Breast Cancer Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 448-75. PMID 25870381 |
0.337 |
|
| 2015 |
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 340-8. PMID 25534386 DOI: 10.1200/Jco.2013.54.6119 |
0.325 |
|
| 2015 |
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, et al. Breast cancer, version 1.2016 featured updates to the NCCN guidelines Jnccn Journal of the National Comprehensive Cancer Network. 13: 1475-1485. |
0.318 |
|
| 2014 |
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens. Clinical Breast Cancer. 14: 396-404. PMID 25239225 DOI: 10.1016/j.clbc.2014.06.006 |
0.321 |
|
| 2014 |
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, et al. Breast cancer version 3.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 542-90. PMID 24717572 |
0.353 |
|
| 2014 |
Miller K, O'Neill AM, Dang CT, Northfelt DW, Gradishar WJ, Goldstein LJ, Mayer IA, Brufsky A, Bloom SH, Sparano JA, Tevaarwerk A, Fox KR, Hendricks CB, Balcueva EP, Sledge GW. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. Journal of Clinical Oncology. 32: 500-500. DOI: 10.1200/JCO.2014.32.15_SUPPL.500 |
0.319 |
|
| 2014 |
Vinayak S, Gray RJ, Adams S, Jensen KC, Manola J, Afghahi A, Goldstein LJ, Ford JM, Badve SS, Telli ML. Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. Journal of Clinical Oncology. 32: 1000-1000. DOI: 10.1200/JCO.2014.32.15_SUPPL.1000 |
0.308 |
|
| 2014 |
Murphy C, Eastwick G, Li T, Johnson M, Goldstein L, Sigurdson E, Bleicher R, Shih J, Anderson P. Questioning the Benefit of Adjuvant Endocrine Therapy (ET) in Elderly Women With Early-Stage Hormone Receptor Positive (HR+) Breast Cancer Treated With Breast-Conserving Surgery (BCS) and Radiation Therapy (RT) International Journal of Radiation Oncology*Biology*Physics. 90: S169. DOI: 10.1016/J.IJROBP.2014.05.673 |
0.303 |
|
| 2013 |
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 753-60; quiz 761. PMID 23847214 DOI: 10.6004/Jnccn.2013.0098 |
0.352 |
|
| 2013 |
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 119: 1140-8. PMID 23065954 DOI: 10.1002/Cncr.27819 |
0.331 |
|
| 2013 |
Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L, Martino S, Davidson N, Sledge G, Sparano J, Badve S. Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S1-07 |
0.338 |
|
| 2012 |
Freedman GM, Li T, Polli LV, Anderson PR, Bleicher RJ, Sigurdson E, Swaby R, Dushkin H, Patchefsky A, Goldstein L. Lymphatic space invasion is not an independent predictor of outcomes in early stage breast cancer treated by breast-conserving surgery and radiation. The Breast Journal. 18: 415-9. PMID 22776042 DOI: 10.1111/j.1524-4741.2012.01271.x |
0.312 |
|
| 2012 |
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 821-9. PMID 22773798 DOI: 10.6004/Jnccn.2012.0086 |
0.3 |
|
| 2012 |
Karp J, Blackford A, Visvanathan K, Rugo H, Moy B, Goldstein L, Stockerl-Goldstein K, Neumayer L, Langbaum T, Hughes M, Weeks J, Wolff A. Abstract S3-5: Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S3-5 |
0.341 |
|
| 2012 |
Tam T, Anderson P, Li T, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan P, Hayes S. Multifocal/Multicentric Breast Cancer Is Associated With Increased Local Recurrence International Journal of Radiation Oncology*Biology*Physics. 84: S187. DOI: 10.1016/J.IJROBP.2012.07.484 |
0.321 |
|
| 2011 |
Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6905-13. PMID 22028489 DOI: 10.1158/1078-0432.CCR-11-0288 |
0.318 |
|
| 2011 |
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, et al. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7194-203. PMID 21933890 DOI: 10.1158/1078-0432.CCR-10-3357 |
0.342 |
|
| 2011 |
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, et al. Invasive breast cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 136-222. PMID 21310842 DOI: 10.6004/Jnccn.2011.0016 |
0.328 |
|
| 2010 |
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, et al. Breast cancer: noninvasive and special situations. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 1182-207. PMID 20971842 DOI: 10.6004/JNCCN.2010.0087 |
0.341 |
|
| 2010 |
Goldstein LJ, Stemmer SM, Schmalfeldt B, Gottschalk N, Cardoso F, Dushkin H, Mala C, Uebler N, Bevan P, Harbeck N. Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 28: TPS131-TPS131. DOI: 10.1200/JCO.2010.28.15_SUPPL.TPS131 |
0.3 |
|
| 2010 |
Anderson P, Freedman G, Li T, Denlinger C, Bleicher R, Sigurdson E, Goldstein L, Cristofanilli M. The Influence of Extensive Intraductal Component on Outcome in Patients with Early Stage Breast Cancer Treated with Breast Conservation Therapy International Journal of Radiation Oncology*Biology*Physics. 78: S209. DOI: 10.1016/J.IJROBP.2010.07.504 |
0.334 |
|
| 2009 |
Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. Journal of the National Comprehensive Cancer Network : Jnccn. 7: S1-S21; quiz S22-3. PMID 19755043 DOI: 10.6004/JNCCN.2009.0079 |
0.317 |
|
| 2009 |
Freedman G, Anderson P, Litwin S, Swaby R, Nicolaou N, Sigurdson E, Ma C, Watkins-Bruner D, Morrow M, Goldstein L. Five-year Results of a Phase II Study of Hypofractionated IMRT with an Incorporated Boost for Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 75: S77. DOI: 10.1016/J.IJROBP.2009.07.194 |
0.301 |
|
| 2008 |
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4092-9. PMID 18678836 DOI: 10.1200/JCO.2008.16.7841 |
0.354 |
|
| 2008 |
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, et al. NCCN Task Force Report: breast cancer in the older woman. Journal of the National Comprehensive Cancer Network : Jnccn. 6: S1-25; quiz S26-7. PMID 18597715 |
0.35 |
|
| 2008 |
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, et al. NCCN Task Force Report: Breast Cancer in the Older Woman Journal of the National Comprehensive Cancer Network. 6: S-1-S-25. DOI: 10.6004/jnccn.2008.2004 |
0.353 |
|
| 2008 |
Denlinger CS, Goldstein LJ. Polychemotherapy for Early Breast Cancer: Results from the International Adjuvant Breast Cancer Chemotherapy Randomized Trial Breast Diseases. 18: 400-401. DOI: 10.1016/S1043-321X(07)80434-6 |
0.355 |
|
| 2007 |
Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, et al. Invasive breast cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 5: 246-312. PMID 17439758 DOI: 10.6004/jnccn.2007.0025 |
0.328 |
|
| 2007 |
Denlinger CS, Goldstein LJ. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer Breast Diseases. 18: 314-316. DOI: 10.1016/S1043-321X(07)80375-4 |
0.335 |
|
| 2007 |
Swaby RF, Goldstein LJ. A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients With Breast Cancer Receiving Adjuvant Chemotherapy Breast Diseases. 18: 312-313. DOI: 10.1016/S1043-321X(07)80370-5 |
0.302 |
|
| 2007 |
Denlinger CS, Goldstein LJ. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial Breast Diseases. 18: 309-310. DOI: 10.1016/S1043-321X(07)80364-X |
0.324 |
|
| 2007 |
Denlinger CS, Goldstein LJ. 3-59 Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclosphosphamide As Adjuvant Therapy for Operable Breast Cancer Breast Diseases. 18: 306-307. DOI: 10.1016/S1043-321X(07)80360-2 |
0.302 |
|
| 2006 |
Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Investigation. 24: 677-81. PMID 17118777 DOI: 10.1080/07357900600981349 |
0.31 |
|
| 2006 |
Freedman GM, Anderson P, Li T, Ross E, Swaby R, Goldstein L. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer. 107: 2552-8. PMID 17061250 DOI: 10.1002/cncr.22291 |
0.335 |
|
| 2006 |
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Jama. 295: 1658-67. PMID 16609087 DOI: 10.1001/jama.295.14.1658 |
0.317 |
|
| 2006 |
Panikkar RP, Goldstein LJ. Does Timing of Adjuvant Chemotherapy Influence the Prognosis After Early Breast Cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG) Breast Diseases. 17: 187-188. DOI: 10.1016/S1043-321X(06)80465-0 |
0.354 |
|
| 2006 |
Goldstein L, Shapiro M. Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial Breast Diseases: a Year Book Quarterly. 16: 377. DOI: 10.1016/S1043-321X(05)80311-X |
0.309 |
|
| 2005 |
Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, et al. Breast cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 3: 238-89. PMID 16002000 |
0.339 |
|
| 2005 |
Denlinger C, Goldstein L. Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide as Neoadjuvant Treatment of Patients With Breast Cancer Breast Diseases: a Year Book Quarterly. 16: 277. DOI: 10.1016/S1043-321X(05)80223-1 |
0.343 |
|
| 2005 |
Freedman G, Anderson P, Li T, Ross E, Swaby R, Goldstein L. Selection of Breast Cancer Patients for an Aromatase Inhibitor After Radiation and Tamoxifen International Journal of Radiation Oncology*Biology*Physics. 63: S242. DOI: 10.1016/J.IJROBP.2005.07.413 |
0.305 |
|
| 2003 |
Trauth D, Goldstein LJ. Taxanes in the adjuvant treatment of breast cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 1: 222-31. PMID 19768881 DOI: 10.6004/JNCCN.2003.0021 |
0.347 |
|
| 2003 |
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 976-83. PMID 12637460 DOI: 10.1200/JCO.2003.02.063 |
0.312 |
|
| 2001 |
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current Treatment Options in Oncology. 2: 157-67. PMID 12057134 DOI: 10.1007/S11864-001-0058-9 |
0.355 |
|
| 2000 |
Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, et al. NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park, N.Y.). 14: 33-49. PMID 11195418 |
0.309 |
|
| 1999 |
Carlson RW, Anderson BO, Bensinger W, Cox C, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith MLP, et al. Update: NCCN practice guidelines for the treatment of breast cancer Oncology. 13: 41-66. PMID 10370921 |
0.304 |
|
| 1998 |
Fowble B, Hanlon AL, Patchefsky A, Freedman G, Hoffman JP, Sigurdson ER, Goldstein LJ. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. International Journal of Radiation Oncology, Biology, Physics. 42: 105-15. PMID 9747827 DOI: 10.1016/S0360-3016(98)00181-3 |
0.316 |
|
| 1997 |
Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, Theriault RL. Update of the NCCN guidelines for treatment of breast cancer Oncology. 11: 199-220. PMID 9430190 |
0.325 |
|
| 1997 |
Fowble B, Hanlon A, Patchefsky A, Hoffman J, Sigurdson E, Goldstein L. 4 The presence of proliferative breast disease with atypia does not influence outcome in invasive breast cancer treated with conservative surgery and radiation International Journal of Radiation Oncology*Biology*Physics. 39: 136. DOI: 10.1016/S0360-3016(97)80560-3 |
0.309 |
|
| 1996 |
Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics. 35: 669-77. PMID 8690632 DOI: 10.1016/0360-3016(96)00185-X |
0.334 |
|
| 1993 |
Sauter ER, Eisenberg BL, Hoffman JP, Ottery FD, Boraas MC, Goldstein LJ, Solin LJ. Postmastectomy morbidity after combination preoperative irradiation and chemotherapy for locally advanced breast cancer World Journal of Surgery. 17: 237-241. PMID 8511920 DOI: 10.1007/BF01658934 |
0.319 |
|
| 1991 |
Bookman MA, Goldstein LJ, Scher RM. Medical management of early-stage breast cancer Current Problems in Cancer. 15: 161-232. PMID 1874006 DOI: 10.1016/0147-0272(91)90020-B |
0.325 |
|
| Show low-probability matches. |